8-K
Current Report
Fulcrum Therapeutics, Inc. Filed Acc 0000950170-22-016633
Results of operations · Exit or restructuring costs
- Item 2.02 Results of operations and financial condition
- Item 2.05 Costs associated with exit or disposal activities
From the SEC's structured data for this filing
Loading fulc-20220811.htm…